Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab biosimilar - Shanghai Henlius Biotech

Next Previous
Drug Profile

Adalimumab biosimilar - Shanghai Henlius Biotech

Alternative Names: Han Da Yuan; Handayuan; HLX-03

Latest Information Update: 15 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Henlius Biotech
  • Developer Shanghai Fosun Pharmaceutical; Shanghai Henlius Biotech
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Plaque psoriasis; Rheumatoid arthritis; Uveitis
  • Registered Behcet's syndrome; Hidradenitis suppurativa; Psoriatic arthritis; Pustular psoriasis; Pyoderma gangrenosum; Spondylarthritis; Ulcerative colitis

Most Recent Events

  • 08 Nov 2024 Shanghai Henlius Biotech and AL-TIRYAQ AL-KHALAWI enter into collaboration to manufacture and commercialise adalimumab biosimilar in Saudi Arabia, Middle East, North Africa and Turkey
  • 28 Aug 2024 Registered for Behcet's syndrome in China (SC) before August 2024
  • 28 Aug 2024 Registered for Crohn's disease in China (SC) before August 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top